BMS scoops up Novo autoimmune program

Bristol-Myers Squibb Co. (NYSE:BMY) acquired an exclusive global license to a research program from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) that modulates the innate immune system to treat autoimmune diseases. Specifics of the program and financial terms were not disclosed. ...